Published in Arch Neurol on December 01, 2009
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Alzheimer mechanisms and therapeutic strategies. Cell (2012) 5.24
Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36
Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science (2010) 3.98
Testing the right target and right drug at the right stage. Sci Transl Med (2011) 3.55
Probing the biology of Alzheimer's disease in mice. Neuron (2010) 2.96
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83
Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol (2011) 2.57
APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology (2011) 2.35
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology (2013) 2.19
Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med (2010) 2.17
MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology (2011) 2.08
Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology (2014) 2.03
Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals. J Neurosci (2013) 2.01
Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology (2012) 2.01
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol (2014) 1.96
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain (2011) 1.89
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement (2013) 1.87
Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex (2011) 1.87
The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med (2010) 1.86
Resting state functional connectivity in preclinical Alzheimer's disease. Biol Psychiatry (2013) 1.86
Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology (2011) 1.83
Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain (2010) 1.80
Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology (2013) 1.74
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging (2010) 1.70
Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A (2011) 1.67
Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage (2011) 1.64
Alzheimer disease. Dis Mon (2010) 1.64
Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology (2011) 1.63
Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia (2011) 1.60
The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis (2010) 1.60
Multimodality Review of Amyloid-related Diseases of the Central Nervous System. Radiographics (2016) 1.53
Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology (2013) 1.53
Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. Arch Neurol (2012) 1.52
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging (2011) 1.51
Preclinical Alzheimer disease and risk of falls. Neurology (2013) 1.49
Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol (2012) 1.48
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther (2013) 1.44
Immunotherapy for Alzheimer's disease. J Intern Med (2011) 1.43
Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging (2012) 1.43
Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry (2014) 1.42
Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol (2011) 1.40
Cerebrovascular disease, β-amyloid, and cognition in aging. Neurobiol Aging (2011) 1.37
Brain aging, Alzheimer's disease, and mitochondria. Biochim Biophys Acta (2011) 1.36
Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. Brain (2014) 1.33
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid. Alzheimers Dement (2011) 1.30
Neurodegenerative disease diagnosis using incomplete multi-modality data via matrix shrinkage and completion. Neuroimage (2014) 1.30
Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. Arch Neurol (2012) 1.29
Aβ Deposition in aging is associated with increases in brain activation during successful memory encoding. Cereb Cortex (2011) 1.26
Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol (2012) 1.25
The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction. JAMA Neurol (2013) 1.25
Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain (2011) 1.23
The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement (2013) 1.22
Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin (2013) 1.21
Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One (2013) 1.21
Seeded strain-like transmission of β-amyloid morphotypes in APP transgenic mice. EMBO Rep (2013) 1.20
Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease. Transl Psychiatry (2013) 1.19
Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radic Biol Med (2012) 1.18
In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Ann Neurol (2013) 1.17
Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun (2014) 1.16
Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer's disease. Alzheimers Dement (2012) 1.11
Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia. Neurology (2013) 1.11
Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review. Alzheimers Res Ther (2013) 1.09
The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons. J Neuropathol Exp Neurol (2012) 1.09
Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther (2011) 1.07
Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment. Alzheimers Dement (2012) 1.07
Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain (2015) 1.07
The effects of aging and Alzheimer's disease on cerebral cortical anatomy: specificity and differential relationships with cognition. Neuroimage (2013) 1.05
Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging. J Alzheimers Dis (2012) 1.04
Neuroimaging measures as endophenotypes in Alzheimer's disease. Int J Alzheimers Dis (2011) 1.04
More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration. Neuron (2014) 1.04
Cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med (2010) 1.03
Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol (2013) 1.03
Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. Neurobiol Aging (2012) 1.02
Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Ann Clin Transl Neurol (2014) 1.00
Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging (2011) 0.99
In vivo characterization of the early states of the amyloid-beta network. Brain (2013) 0.99
The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly. Alzheimers Dement (2013) 0.98
Brain imaging in the study of Alzheimer's disease. Neuroimage (2011) 0.97
Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions. Alzheimers Res Ther (2010) 0.97
Quantitative structural MRI for early detection of Alzheimer's disease. Expert Rev Neurother (2010) 0.96
Protein binding in patients with late-life depression. Arch Gen Psychiatry (2011) 0.94
Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med (2010) 0.93
Enrichment and stratification for predementia Alzheimer disease clinical trials. PLoS One (2012) 0.93
Cerebral amyloid PET imaging in Alzheimer's disease. Acta Neuropathol (2013) 0.93
Structural imaging measures of brain aging. Neuropsychol Rev (2014) 0.91
Disclosure of amyloid imaging results to research participants: has the time come? Alzheimers Dement (2013) 0.91
Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation. PLoS One (2013) 0.90
Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement (Amst) (2015) 0.90
In vivo human amyloid imaging. Curr Alzheimer Res (2011) 0.90
Dementia screening, biomarkers and protein misfolding: Implications for public health and diagnosis. Prion (2011) 0.89
Amyloid imaging and cognitive decline in nondemented oldest-old: the 90+ Study. Alzheimers Dement (2012) 0.88
Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD. Neurology (2014) 0.88
Nonfluent/agrammatic PPA with in-vivo cortical amyloidosis and Pick's disease pathology. Behav Neurol (2013) 0.88
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology (1993) 47.72
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage (2006) 25.52
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab (1996) 9.49
Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology (2006) 8.97
Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol (2001) 8.88
The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord (2006) 8.04
Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol (2008) 7.95
Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol (1998) 5.93
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex (2008) 5.36
Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem (2003) 5.34
Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol (2003) 5.17
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71
PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging (2007) 4.47
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology (2007) 4.24
Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA (2003) 4.16
Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol (2001) 3.80
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol (2003) 3.75
Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology (2006) 3.69
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol (2009) 3.60
Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol (2009) 3.35
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol (2009) 3.34
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol (2003) 2.72
Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol (2009) 2.66
Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol (2008) 2.62
Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol (1995) 2.62
Memory impairment on free and cued selective reminding predicts dementia. Neurology (2000) 2.58
Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology (1991) 2.53
MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology (2005) 2.48
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol (2009) 2.42
Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol (2008) 2.40
Frontal-hippocampal double dissociation between normal aging and Alzheimer's disease. Cereb Cortex (2004) 1.91
Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord (2003) 1.67
Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology (2004) 1.64
CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology (2005) 1.46
Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol (2009) 1.44
Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology (2007) 1.43
Antecedent biomarkers of Alzheimer's disease: the adult children study. J Geriatr Psychiatry Neurol (2005) 1.16
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet (2006) 13.16
Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci (2005) 12.85
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb Cortex (2005) 9.73
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Disruption of large-scale brain systems in advanced aging. Neuron (2007) 8.12
Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet (2006) 7.90
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron (2005) 7.53
Brain work and brain imaging. Annu Rev Neurosci (2006) 6.99
National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke (2006) 6.94
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature (2008) 6.89
Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry (2008) 6.73
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol (2008) 5.58
The role of apolipoprotein E in Alzheimer's disease. Neuron (2009) 5.55
Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci (2011) 5.40
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 5.09
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci (2003) 5.00
A genome-wide association study of alcohol dependence. Proc Natl Acad Sci U S A (2010) 4.94
Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science (2009) 4.92
Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88
ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol (2009) 4.59
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature (2009) 4.43
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron (2004) 4.21
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
The default mode network and self-referential processes in depression. Proc Natl Acad Sci U S A (2009) 4.05
Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron (2008) 3.98
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature (2012) 3.80
Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry (2009) 3.72
Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology (2006) 3.69
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol (2009) 3.60
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol (2011) 3.56
Long-term cognitive decline in older subjects was not attributable to noncardiac surgery or major illness. Anesthesiology (2009) 3.56
Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci (2002) 3.50
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol (2012) 3.48
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol (2013) 3.46
Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proc Natl Acad Sci U S A (2010) 3.42
apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest (2008) 3.36
Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol (2009) 3.35
Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab (2006) 3.35
Regional aerobic glycolysis in the human brain. Proc Natl Acad Sci U S A (2010) 3.25
Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology (2007) 3.22
Aging, sexual dimorphism, and hemispheric asymmetry of the cerebral cortex: replicability of regional differences in volume. Neurobiol Aging (2004) 3.18
Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One (2012) 3.11
Sleep quality and preclinical Alzheimer disease. JAMA Neurol (2013) 3.11
HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol (2006) 3.00
APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. J Neurosci (2010) 2.99
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
A quantitative-trait genome-wide association study of alcoholism risk in the community: findings and implications. Biol Psychiatry (2011) 2.87
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. Am J Med Genet B Neuropsychiatr Genet (2009) 2.86
Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol (2012) 2.84
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 2.81
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol (2011) 2.81
Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ ) deposition. Proc Natl Acad Sci U S A (2010) 2.80
Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 2.78
Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci (2009) 2.76
Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol (2005) 2.76
Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol (2003) 2.72
Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Sci Transl Med (2012) 2.66
The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans. Cancer Res (2009) 2.63